ABIVAX启动IPO在Euronext巴黎的监管市场

StephenW

ABIVAX Launches IPO on the Regulated Market of Euronext in Paris

Share capital increase of €43,6 million, that can reach a maximum of €57,7 million after exercise of the Extension Clause and of the Overallotment Option

Subscription undertakings representing €33 million

Indicative price range: €18.26 - €24.34 per share

Placement period: from June 5 to June 22

Eligible for French PEA PME investment regime

PARIS-- Regulatory News:

ABIVAX (Paris: ABVX) DEVELOPS NOVEL MEDICINES TO CONTROL LIFE-THREATENING VIRAL DISEASES

    ABIVAX's goal is to become one of the global leaders of anti-viral treatments
    Two first in class products with long-lasting effect in advanced clinical trials, that have demonstrated efficacy against chronic Hepatitis B and safety in the treatment of HIV
    A unique anti-viral platform "killing" viral RNA
    Pioneering partnerships with Cuban Excellence in vaccines and anti-virals

ABIVAX, a clinical stage biotech company specializing in the discovery, development and commercialization of anti-viral compounds and human vaccines, today announced the launch of its Initial Public Offering (IPO) on Euronext's regulated market in Paris (Euronext Paris). The French Autorité des marchés financiers (AMF) has granted visa number 15-255 dated June 4, 2015 to the French prospectus relating to the IPO of ABIVAX, which comprises a registration document registered with the AMF May 19th with the number I.15-040 and a securities note (including a summary of the prospectus).

HIGHLIGHTS OF THE OFFERING

    Indicative price range: €18.26 to €24.34 per share
    Global Placement aimed primarily at institutional investors in France and in certain other countries, excluding notably the United States of America, Canada, Australia, and Japan (the "Global Placement") and a public offering in France in the form of an open price aimed primarily at retail investors (the "OPO")
    Initial size of the Offering: 2,046,949 new shares to be issued through a share capital increase, i.e. approximately €43.6 million (based on the midpoint of the indicative price range at €21.3 per share); the size of the offering includes €2 million of debt offset
    Extension Clause: a maximum of 307,042 additional new shares. Following full exercise of the Extension Clause, the Offering can reach a maximum of 2,353,991 new shares, i.e. an Offering size of approximately €50.1 million (based on the midpoint of the indicative price range)
    Overallotment option: a maximum of 353,098 additional new shares. Following full exercise of the overallotment option, the Offering can reach a maximum of 2,707,089 new shares, i.e. an Offering size of approximately €57.7 million (based on the midpoint of the indicative price range)
    Closing of the Offering : June 22 2015, 6:00 pm CET
    Determination of the Offering Price planned on June 23. Beginning of trading on the regulated market of Euronext in Paris due on June 26 (ISIN: FR0012333284; Ticker ABVX)

SUBSCRIPTION UNDERTAKINGS OF UP TO €33 MILLION

The funds managed by Truffle Capital have made a commitment to participate in this Offering for an order of up to €5 million, i.e. 11.5% of the gross amount of the Offering (excluding the Extension Clause and the OverAllotment Option). This subscription commitment will be carried out as follows: as a debt off-set of €2 million as a cash contribution and up to €3 million in cash.

Moreover, 5 new investors, Aviva Investors (€11 million), Amundi Groupe (€4 million), SCOR Global Investments (€2 million), Dr Antonio Ligresti (€10 million) and Jacques Veyrat (€1 million) have committed to participate in the Offering for a total amount of €28 million, ie 64.2% of the gross amount of the Offering (excluding exercise of the Extension Clause and Overallotment Option)

The total amount of received subscription undertakings is €33 million, ie:

    75.69% of the gross amount of the Offering, based on the midpoint of the indicative price range (€21.3 per share) before exercise of the Extension Clause and Overallotment Option (2,046,949 new shares) ;
    57.23% of the gross amount based on the midpoint of the indicative price range (€21.3 per share) after exercise of the Extension Clause and Overallotment Option (2,707 089 new shares).

ABIVAX is a biotechnology company focused on becoming one of the global leaders in the discovery, development and commercialization of anti-viral compounds and human vaccines to treat some of the world's most life-threatening viral diseases, including chronic Hepatitis B (CHB) and HIV/AIDS, as well as Ebola, Dengue and Chikungunya. The Company is based in Paris, Evry and Montpellier (France).

ABIVAX's key strengths and strategic priorities are:

    Two lead compounds: ABX203 (chronic Hepatitis B) and ABX464 (HIV/AIDS) have delivered results to-date suggesting that they can respectively bring real advantages to the treatment of chronic Hepatitis B (World Health Organization/WHO estimates 2 billion people worldwide have been infected with Hepatitis B, including 350 million patients with the chronic form of this disease) and HIV/AIDS (ABIVAX estimates total worldwide costs of treating AIDS of up to $18 billion annually). They could be marketed as soon as 2017 and 2020 respectively;
    Pioneering relationships with Cuba's world-class vaccine institutes as a way to build its product pipeline;
    Current clinical trials likely to confirm long term control of viral load and potential to serve as a functional cure along with simpler, more cost effective treatment regimens;
    IPO that aims to finance the clinical development programs for both lead products and specifically pivotal study in Asia for ABX203 in the treatment of chronic Hepatitis B and Phase II clinical trial against HIV/AIDS.
    Together with a highly experienced and international management team, this strategy will enable ABIVAX to achieve a number of important milestones in the treatment of viral disease.

Professor Hartmut Ehrlich, M.D., CEO of ABIVAX, said: "ABIVAX was founded to become a global leader for the treatment of severe and life-threatening viral infections. Our two lead compounds ABX203 (chronic Hepatitis B) and ABX464 (HIV/AIDS), both first-in-class anti-virals, have delivered results to-date that suggest that they can substantially improve the treatment options for patients with chronic Hepatitis B and HIV. We are confident that the current clinical trials with these compounds will confirm and extend their clinical differentiation of long-term control of viral load in the patients. With our advanced clinical development pipeline, our prestigious research partnerships around the world and a highly experienced management team, ABIVAX has the key elements needed to deliver its value creation strategy."

ABIVAX: a pioneering biotech company with an advanced pipeline already in clinic

ABIVAX has 2 first-in-class compounds in advanced clinical development: ABX203, a therapeutic vaccine that could be a cure for chronic Hepatitis B and ABX464, a novel small molecule against HIV with a number of important potential competitive advantages, including the lack of induced resistance and a long-lasting effect. The broader ABIVAX portfolio includes additional anti-viral compounds that may enter the clinical phase in the coming 12-18 months.

Alongside its cutting-edge technology, ABIVAX has also pioneered relationships with Cuba's world-class vaccine institutes (CIGB - Center for Genetic Engineering and Biotechnology, Finlay Institute) as a way to build its product pipeline. Through these relationships, ABIVAX has secured broad access to Cuban R&D and product manufacturing. Today, the Cuban life science industry is based on world-class science and cutting-edge technology research.

These relationships have already resulted in a number of important deals for ABIVAX including the exclusive in-licensing of ABX203 (chronic Hepatitis B) and of a novel antiviral compound against Dengue, and the acquisition of the distribution rights of three commercial vaccines against Typhoid, Meningococcus B&C and Leptospirosis, for which ABIVAX has acquired exclusive and non-exclusive distribution rights. These three vaccines could be marketed as early as 2015, subject to the signing of distribution agreements with local partners. ABIVAX is also in advanced discussions to acquire other products already at clinical stage.

ABX203: a therapeutic vaccine against chronic Hepatitis B currently in pivotal trial

ABX203 is a therapeutic vaccine composed of 2 recombinant proteins from the Hepatitis B vaccine, the surface antigen (HBsAg) and the nucleocapsid (core) structure (HBcAg). This combination of antigens has been designed to induce immune response in patients suffering from chronic Hepatitis B.

Hepatitis B virus (HBV) infection is a major public health problem worldwide. People infected with HBV can develop persistent infection, which can lead to chronic disease and death from cirrhosis or liver cancer (hepatocellular carcinoma). According to the World Health Organization (WHO), an estimated 2 billion people worldwide have been infected with HBV, and more than 350 million people, or 5% of the world's population, have chronic, lifelong infections. Around 1 to 1.5 million patients die every year due to the consequences of viral Hepatitis B.

ABX203 was in-licensed in 2013 from the CIGB, following the completion of successful phase I, I/IIa and II/III clinical trials run by CIGB in Cuba and Bangladesh. ABIVAX owns an exclusive license to develop and commercialize ABX203 in more than 80 countries in Asia, Europe and Africa.

A pivotal Phase IIb/III study with ABX203 is currently recruiting patients in the Asia-Pacific region under the responsibility of ABIVAX. Previous clinical studies have revealed that ABX203 can deliver a significant improvement in the treatment of chronic Hepatitis B via controlling viral load for a much longer period of time when compared to current treatment options. ABX203 could be marketed as soon as 2017.

StephenW

ABIVAX启动IPO在Euronext巴黎的监管市场

股本增加了43,6亿€，行使扩展条款后和超额配股权，可以达到最大的57,7亿€

代表33 million€认购承诺

指示性价格区间：€18.26 - €24.34每股

募集期限：自6月5日至6月22日

有资格获得法国PEA PME投资制度

PARIS--监管新闻：

ABIVAX（巴黎：ABVX）开发新药驾驭生命危险病毒性疾病

    ABIVAX的目标是成为抗病毒治疗的全球领导者之一
    两个第一类产品的长期持久的影响在晚期临床试验中，已证明对慢性乙型肝炎的疗效及安全性的艾滋病毒治疗
    独特的防病毒平台“杀”病毒RNA
    与古巴卓越的疫苗和抗病毒药物的伙伴关系创业

ABIVAX，临床阶段的生物技术公司，专门从事抗病毒化合物和人用疫苗的发现，开发和商业化，今天宣布推出其首次公开募股（IPO）在泛欧交易所的监管市场在巴黎（巴黎Euronext）的。法国法国金融市场管理局（AMF）已授予日2015年6月4日于与ABIVAX的IPO，这包括与AMF 5月19日与数字注册登记文件法国签证的招股数量15-255 I.15- 040和证券说明（包括招股说明书的摘要）。

此次发行的亮点

    指示性价格区间：€18.26至€24.34每股
    全球布局主要针对机构投资者在法国和其他一些国家，特别是排除美国，加拿大，澳大利亚和日本（“全球布局”）的美国公开招股在法国的公开价格，旨在形式主要是在散户投资者（以下简称“OPO”）
    本次发行的初始大小：要通过增资扩股发行2046949股新股，即约43.6 million€（根据指示价格区间为€21.3％份额的中点）;在发行规模包括2个€万元抵债
    扩展条款：最高307042股额外新股份。继全额行使扩展条款的，本次发行可达到最高2353991股新股，即约50.1 million€的发行规模（根据指示价格区间的中点）
    超额配股权：最多353098股额外新股份。继全面行使超额配股权后，发行可达到最高2707089股新股，即约57.7 million€的发行规模（根据指示价格区间的中点）
    截止本次发行：2015年6月22日，下午6:00 CET
    的发行价格确定在六月23计划开始交易泛欧交易所巴黎规范的市场上，由于6月26日（ISIN：FR0012333284;北京时间ABVX）

起来到€3,300万元认购经营

由松露资本管理的基金取得了参加本次发售的高达500万€的顺序，本次发行的总额（不包括扩展条款及超额配股权）的，即11.5％的承诺。该认购承诺将进行如下：作为债务抵销200万€为现金出资和最多3€万元现金。

此外，5个新的投资者，英杰华投资（每年1100万€），东方汇阳狮集团（4元€），SCOR环球投资（2元€），安东尼奥Ligresti博士（10元€）和雅克Veyrat（1元€）已承诺参与发行了总额2800万€，本次发行总额的64.2，即％（不包括行使扩展条款及超额配股权的）

收到认购承诺总额则在3300万€，即：

    总额本次发行的基础上，指示价格范围（€21.3股）行使扩展条款及超额配股权（2046949股新股）前的中点的75.69％;
    57.23％行使扩展条款及超额配股权（2707 089股新股）后，根据指示性价格区间（€21.3％的份额）的中点总额的。

ABIVAX是一家生物技术公司，专注于成为抗病毒化合物和人用疫苗的发现，开发和商业化的全球领导者之一，治疗一些世界上最致命的病毒病，包括慢性乙型肝炎（CHB）和HIV /艾滋病，以及埃博拉病毒，登革热和基孔肯雅。该公司总部设在巴黎，埃夫里和蒙彼利埃（法国）。

ABIVAX的主要优势和战略重点是：

    两个铅化合物：ABX203（慢性乙肝）和ABX464（HIV / AIDS）已经交付成果的最新建议，他们可以分别带来真正的优势，以慢性乙型肝炎（世界卫生组织/世界卫生组织估计有20十亿人在全球有治疗已感染乙肝，包括3.5亿患者对此病的慢性形式）和艾滋病毒/艾滋病（ABIVAX估计，每年处理高达18美元十亿艾滋病的全球总成本）。他们可以在市场上销售，只要2017年分别和2020年;
    与古巴的世界一流的疫苗研究机构，以此来打造其产品线开拓性的关系;
    目前的临床试验中容易确认长期控制病毒载量和潜在的充当连同更简单，更经济有效的治疗方案的官能固化;
    IPO，旨在资助临床开发项目为铅制品，特别关键的研究在亚洲ABX203慢性乙肝治疗和II期临床试验防治艾滋病毒/艾滋病。
    再加上具有丰富经验和国际化的管理团队，这一策略将使ABIVAX实现病毒性疾病的治疗了一些重要的里程碑。

哈特穆特埃利希教授，医学博士，ABIVAX的首席执行官说：“ABIVAX成立，成为为严重和危及生命的病毒性感染治疗的全球领导者我们两家铅化合物ABX203（慢性乙肝）和ABX464（HIV / AIDS） ，无论是第一次在类抗病毒药物，已经交付成果的最新的建议，他们可以大大提高患者的慢性乙肝和艾滋病毒的治疗方案。我们相信，与这些化合物目前的临床试验将确认并延长长期控制病毒载量的患者的临床分化。我们凭借先进的临床发展管道，我们在世界各地著名的科研合作伙伴关系和经验丰富的管理团队，有ABIVAX提供其价值创造战略所需的关键要素。 “

ABIVAX：开拓生物技术公司与已在临床上一种先进的流水线

ABIVAX具有2先入类化合物在先进的临床发展：ABX203，治疗性疫苗，可能是一种治疗慢性乙型肝炎和ABX464，抗HIV的新型小分子与许多重要的潜在的竞争优势，包括缺乏诱导性和持久的效果。大盘ABIVAX组合包括可能在未来12-18个月进入临床阶段的其他抗病毒化合物。

除了其尖端的技术，ABIVAX还率先与古巴的世界一流的疫苗研究机构的关系（CIGB - 中心遗传工程和生物技术，芬利研究所），以此来构建其产品线。通过这些关系，ABIVAX已获得广泛访问古巴的研发和产品制造。如今，古巴生命科学产业是基于世界级的科学和前沿技术研究。

这些关系已经造成了对登革热的新型抗病毒化合物的一些重要的交易为ABIVAX包括独家许可ABX203（慢性乙肝）和，以及收购的三家商业疫苗预防伤寒，脑膜炎球菌的经销权B＆C和钩端螺旋体病，为此ABIVAX已经获得独家和非独家经销权。这三种疫苗可以在市场上销售，早在2015年，但须与当地合作伙伴分销协议的签字仪式。 ABIVAX也是先进的讨论已经在临床分期收购其他产品。

ABX203：在关键试验对慢性乙肝治疗性疫苗目前

ABX203是治疗性疫苗从乙型肝炎疫苗由2重组蛋白，所述表面抗原（HBsAg）和核衣壳（芯）结构（核心抗原）。抗原的组合已被设计用于诱导在患者的慢性乙型肝炎患免疫应答

乙型肝炎病毒（HBV）感染是世界范围内重要的公共卫生问题。感染HBV的人可以开发持续感染，其可导致慢性疾病和死亡的肝硬化或肝癌（肝细胞癌）。据世界卫生组织（WHO），估计有200十亿人在全球已感染乙肝病毒，超过3.5亿人，占世界人口的5％，有慢性，终身感染。大约1〜1.5万患者，每年死于肝炎病毒B的后果

ABX203从CIGB的许可在2013年，成功地完成阶段下列I，I / IIa和II / CIGB由古巴和孟加拉国的运行III期临床试验。 ABIVAX拥有独家授权开发并在超过80个国家在亚洲，欧洲和非洲的商业化ABX203。

一个关键IIb / III期研究，ABX203目前正在招募患者在亚太地区的下ABIVAX的责任。先前的临床研究表明，ABX203可以通过时相比，目前的治疗选择控制病毒载量的时间长得多的时间递送治疗慢性乙型肝炎的治疗显著改善。 ABX203能尽快2017年上市销售。

yelanglms

A pivotal Phase IIb/III study with ABX203 is currently recruiting patients in the Asia-Pacific region under the responsibility of ABIVAX. Previous clinical studies have revealed that ABX203 can deliver a significant improvement in the treatment of chronic Hepatitis B via controlling viral load for a much longer period of time when compared to current treatment options. ABX203 could be marketed as soon as 2017.

ABX203 最快于2017年上市。比现有方法更长时间控制病毒载量。

yelanglms

ABX203 最快于2017年上市。
若ABX203真的有效果，真的能上市。那正是开创新路了。即使不能根治，以后也可能在改进的时候根治。

42年才知道

不明觉厉，顶

君看一叶舟

治疗性疫苗，古巴在药物研发方面这么领先？

zgct

，